Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein–Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab

Satoshi Honda; Rishi Puri; Todd Anderson; John J. P. Kastelein; Danielle M. Brennan; Helina Kassahun; Ransi Somaratne; Scott M. Wasserman; Steve E. Nissen; Stephen J. Nicholls

doi:https://doi.org/10.1016/j.jcmg.2021.11.014

Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein–Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab

Satoshi Honda, Rishi Puri, Todd Anderson, John J. P. Kastelein, Danielle M. Brennan, Helina Kassahun, Ransi Somaratne, Scott M. Wasserman, Steve E. Nissen, Stephen J. Nicholls

Research output: Contribution to journal › Comment/Letter to the editor › Academic

2 Citations (Scopus)

Original language	English
Pages (from-to)	709-711
Number of pages	3
Journal	JACC. Cardiovascular imaging
Volume	15
Issue number	4
DOIs	https://doi.org/10.1016/j.jcmg.2021.11.014
Publication status	Published - 1 Apr 2022

Access to Document

https://doi.org/10.1016/j.jcmg.2021.11.014

Cite this

Honda, S., Puri, R., Anderson, T., Kastelein, J. J. P., Brennan, D. M., Kassahun, H., Somaratne, R., Wasserman, S. M., Nissen, S. E., & Nicholls, S. J. (2022). Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein–Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab. JACC. Cardiovascular imaging, 15(4), 709-711. https://doi.org/10.1016/j.jcmg.2021.11.014

@article{6af2a0776a954687875fdb3d0429db10,

title = "Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein–Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab",

author = "Satoshi Honda and Rishi Puri and Todd Anderson and Kastelein, {John J. P.} and Brennan, {Danielle M.} and Helina Kassahun and Ransi Somaratne and Wasserman, {Scott M.} and Nissen, {Steve E.} and Nicholls, {Stephen J.}",

note = "Funding Information: Dr Puri has received consulting fees from Cerenis, Sanofi-Aventis and Amgen Inc. Dr Anderson has received honoraria (<$5,000) for speaking from Amgen Inc, Bayer, and Sanofi; and was the local principal investigator on clinical research studies for Amgen Inc and Dalcor. Dr Kastelein has received personal consulting fees from Sanofi, Affiris, Akarna Therapeutics, Amgen Inc, CSL Behring, Regeneron, Staten Biotech, Madrigal, The Medicines Company, Kowa, Lilly, Esperion, Gemphire, Ionis Pharmaceuticals, and Akcea Pharmaceuticals. Dr Kassahun is an employee and stockholder of Amgen Inc. Dr Somaratne was an employee of Amgen Inc; owns stock in Amgen Inc; and was an inventor on at least one patent application owned by Amgen relating to evolocumab. Dr Wasserman was an employee of Amgen Inc; owns stock in Amgen Inc; and was an inventor on multiple patents and patent applications owned by Amgen Inc relating to evolocumab during the conduct of the study. Dr Nissen reports that the Cleveland Clinic Center for Clinical Research has received funding to perform clinical trials from Abbvie, AstraZeneca, Amgen Inc, Cerenis, Eli Lilly, Esperion, Pfizer, The Medicines Company, Takeda, and Orexigen, he is involved in these clinical trials, but receives no personal remuneration for his participation; and consults for many pharmaceutical companies, but requires them to donate all honoraria or consulting fees directly to charity so that he receives neither income nor a tax deduction. Dr Nicholls has received research support from AstraZeneca, Amgen, Anthera, CSL Behring, Cerenis, Eli Lilly, Esperion, Resverlogix, Novartis, InfraReDx, and Sanofi-Regeneron and is a consultant for Amgen, Akcea, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Kowa, Merck, Takeda, Pfizer, Sanofi-Regeneron, and Novo Nordisk. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.",

year = "2022",

month = apr,

day = "1",

doi = "https://doi.org/10.1016/j.jcmg.2021.11.014",

language = "English",

volume = "15",

pages = "709--711",

journal = "JACC. Cardiovascular imaging",

issn = "1936-878X",

publisher = "Elsevier Inc.",

number = "4",

}

Honda, S, Puri, R, Anderson, T, Kastelein, JJP, Brennan, DM, Kassahun, H, Somaratne, R, Wasserman, SM, Nissen, SE & Nicholls, SJ 2022, 'Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein–Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab', JACC. Cardiovascular imaging, vol. 15, no. 4, pp. 709-711. https://doi.org/10.1016/j.jcmg.2021.11.014

TY - JOUR

T1 - Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein–Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab

AU - Honda, Satoshi

AU - Puri, Rishi

AU - Anderson, Todd

AU - Kastelein, John J. P.

AU - Brennan, Danielle M.

AU - Kassahun, Helina

AU - Somaratne, Ransi

AU - Wasserman, Scott M.

AU - Nissen, Steve E.

AU - Nicholls, Stephen J.

N1 - Funding Information: Dr Puri has received consulting fees from Cerenis, Sanofi-Aventis and Amgen Inc. Dr Anderson has received honoraria (<$5,000) for speaking from Amgen Inc, Bayer, and Sanofi; and was the local principal investigator on clinical research studies for Amgen Inc and Dalcor. Dr Kastelein has received personal consulting fees from Sanofi, Affiris, Akarna Therapeutics, Amgen Inc, CSL Behring, Regeneron, Staten Biotech, Madrigal, The Medicines Company, Kowa, Lilly, Esperion, Gemphire, Ionis Pharmaceuticals, and Akcea Pharmaceuticals. Dr Kassahun is an employee and stockholder of Amgen Inc. Dr Somaratne was an employee of Amgen Inc; owns stock in Amgen Inc; and was an inventor on at least one patent application owned by Amgen relating to evolocumab. Dr Wasserman was an employee of Amgen Inc; owns stock in Amgen Inc; and was an inventor on multiple patents and patent applications owned by Amgen Inc relating to evolocumab during the conduct of the study. Dr Nissen reports that the Cleveland Clinic Center for Clinical Research has received funding to perform clinical trials from Abbvie, AstraZeneca, Amgen Inc, Cerenis, Eli Lilly, Esperion, Pfizer, The Medicines Company, Takeda, and Orexigen, he is involved in these clinical trials, but receives no personal remuneration for his participation; and consults for many pharmaceutical companies, but requires them to donate all honoraria or consulting fees directly to charity so that he receives neither income nor a tax deduction. Dr Nicholls has received research support from AstraZeneca, Amgen, Anthera, CSL Behring, Cerenis, Eli Lilly, Esperion, Resverlogix, Novartis, InfraReDx, and Sanofi-Regeneron and is a consultant for Amgen, Akcea, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Kowa, Merck, Takeda, Pfizer, Sanofi-Regeneron, and Novo Nordisk. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2022/4/1

Y1 - 2022/4/1

UR - http://www.scopus.com/inward/record.url?scp=85127193329&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.jcmg.2021.11.014

DO - https://doi.org/10.1016/j.jcmg.2021.11.014

M3 - Comment/Letter to the editor

C2 - 34922870

SN - 1936-878X

VL - 15

SP - 709

EP - 711

JO - JACC. Cardiovascular imaging

JF - JACC. Cardiovascular imaging

IS - 4

ER -

Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein–Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab

Access to Document

Other files and links

Cite this